Indivior Files 2025 Annual Report to Security Holders

Ticker: INDV · Form: ARS · Filed: Mar 27, 2026 · CIK: 0001625297

Sentiment: neutral

Topics: annual-report, pharmaceuticals, sec-filing

TL;DR

Indivior dropped its 2025 ARS on 3/27/26. Check financials.

AI Summary

Indivior Pharmaceuticals, Inc. filed an Annual Report to Security Holders (ARS) on March 27, 2026, for the period ending December 31, 2025. The filing, with SEC Accession No. 0001104659-26-035513, provides a comprehensive overview of the company's performance and financial standing for the fiscal year 2025. The report details the company's operations and outlook as a pharmaceutical preparations entity.

Why It Matters

This filing provides shareholders and potential investors with a detailed look at Indivior's financial health and strategic direction for the 2025 fiscal year, influencing investment decisions.

Risk Assessment

Risk Level: low — This is a routine annual filing providing historical financial information and does not contain new material events or significant forward-looking statements that would indicate immediate risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this ARS filing?

The primary purpose of this ARS filing is to provide an Annual Report to Security Holders for the period ending December 31, 2025.

When was this ARS filing accepted by the SEC?

This ARS filing was accepted by the SEC on March 27, 2026.

What is the CIK number for Indivior Pharmaceuticals, Inc.?

The CIK number for Indivior Pharmaceuticals, Inc. is 0001625297.

What is the fiscal year end for Indivior Pharmaceuticals, Inc.?

The fiscal year end for Indivior Pharmaceuticals, Inc. is December 31.

What is the SIC code for Indivior Pharmaceuticals, Inc.?

The SIC code for Indivior Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form ARS (Form ARS) was filed with the SEC on March 27, 2026 regarding Indivior Pharmaceuticals, Inc. (INDV).

View full filing on EDGAR

View Full Filing

View this ARS filing on SEC EDGAR

View on Read The Filing